Integrating Newer Therapies into Management of Adult ALL

home / peer-exchange / integrating-newer-therapies-into-management-of-adult-all

EP. 1: Prognostic Factors Which Impact ALL Management

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 13th 2021

EP. 2: Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 13th 2021

EP. 3: Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 13th 2021

EP. 4: Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 21st 2021

EP. 5: Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 28th 2021

EP. 6: Role of MRD Testing in Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

January 28th 2021

EP. 7: Treatment of Acute Lymphoblastic Leukemia in the Community Setting

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 4th 2021

EP. 8: Managing MRD-Positive Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 4th 2021

EP. 9: Managing MRD-Negative Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 11th 2021

EP. 10: Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 11th 2021

EP. 11: Approach to Managing Relapsed Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 18th 2021

EP. 12: CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 18th 2021

EP. 13: CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 25th 2021

EP. 14: Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

February 25th 2021

EP. 15: Evolving Field of Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

March 4th 2021

EP. 16: ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

By Richard M. Stone, MD, Dana-Farber Cancer Institute
Ryan D. Cassaday, MD, University of Washington/Fred Hutch

March 4th 2021

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512